Full Press Release Details
Pharmaceuticals Appoints Jeffrey S. Hackman as Chief Executive Officer and Director
Industry Leader Brings Extensive Commercialization and Oncology Expertise ~
Leadership Role at Critical Time to Expand Use of PEDMARK , the First and Only Approved Treatment to Reduce the Risk of Cisplatin-Induced
TRIANGLE PARK, N.C., August 5, 2024 - Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty
pharmaceutical company, today announced the appointment of Mr. Jeff Hackman as its Chief Executive Officer (CEO) and a member of the
Board of Directors, effective on or about August 16, 2024. Jeff will guide Fennec's strategic direction for operational success
in the expansion of PEDMARK use in community oncology and the adolescent and young adult (AYA) population.
appointment comes at a pivotal time for Fennec as we continue to advance PEDMARK , the first and only therapy approved in the U.S.
and Europe to reduce the risk of permanent damage from cisplatin-induced ototoxicity in pediatric cancer patients," said Dr. Khalid
Islam, Chairman of Fennec Pharmaceuticals. "We are confident that Jeff's deep expertise in the commercialization of new therapies
across multiple oncology indications, and extensive experience leading organizational growth and transformation, will bring tremendous
Jeff brings to Fennec more than 30 years of commercial
leadership experience, including oversight of more than 10 product launches across a wide range of therapeutic areas and markets. His
tenure in oncology spans the last 12 years across Sigma Tau, Baxalta, Shire, and EUSA Pharma, where he was responsible for the U.S. commercial
organizations and managing the company's product portfolio in multiple franchises, which generated billions in revenues over the
years. More specifically, Jeff has successfully commercialized products that are specifically relevant to the PEDMARK
markets, including the outpatient oncology community and the AYA population.
"I am excited to lead Fennec and look forward
to working with management and the Board of Directors to bring this much-needed treatment to oncology patients," said Jeffrey S.
Hackman, incoming chief executive officer of Fennec Pharmaceuticals.
who has served as Fennec's CEO since 2009, will remain a member of the Board of Directors. "Rosty's unwavering
commitment and leadership since 2009 has been critical to Fennec in bringing a much-needed therapy to the oncology population at risk
of irreversible hearing loss, which can have a profound lifelong impact on patients," said Khalid Islam.
Fennec Pharmaceuticals Inc. is a specialty pharmaceutical
company focused on the development and commercialization of PEDMARK and Pedmarqsi
to reduce the risk of cisplatin-induced ototoxicity in pediatric patients. Further, PEDMARK received FDA approval in September 2022,
and Pedmarqsi received European Commission Marketing Authorization in June 2023 and U.K. approval in October 2023. PEDMARK has received
Orphan Drug Exclusivity in the U.S. for seven years of market protection and Pedmarqsi has received Pediatric Use Marketing Authorization
in Europe, which includes eight years plus two years of data and market protection. Fennec has a license agreement with Oregon Health
and Science University (OHSU) for exclusive worldwide license rights to intellectual property directed to sodium thiosulfate and its
use for chemoprotection, including the reduction of risk of ototoxicity induced by platinum chemotherapy, in humans. For more information,
please visit www.fennecpharma.com.
further information, please contact:
Chief Financial Officer
Fennec Pharmaceuticals Inc.
Corporate and Media:
Elixir Health Public Relations